BringhurstF.R.Regulation of calcium and phosphate homeostasis. In: DeGrootL.J., JamesonJ.L., eds. Endocrinology, Philadelphia: W.B. Saunders Co.2001; 1029–52.
2.
TakedaE., TaketaniY., SawadaN., SatoT., YamamotoH.The regulation and function of phosphate in the human body. Biofactors2004; 21: 345–55.
3.
TakedaE., YamamotoH., NashikiK., SatoT., AraiH., TaketaniY.Inorganic phosphate homeostasis and the role of dietary phosphorus. J Cell Mol Med2004; 8: 191–200.
4.
ForsterI.C., HernandoN., BiberJ., MurerH.Proximal tubular handling of phosphate: a molecular perspective. Kidney Int2006; 70: 1548–59.
5.
MiyamotoK., ItoM., TatsumiS., KuwahataM., SegawaH.New aspect of renal phosphate reabsorption: the type IIc sodium-dependent phosphate transporter. Am J Nephrol2007; 27: 503–15.
6.
EconsM.J., DreznerM.K.Tumor-induced osteomalacia-unveiling a new hormone. N Engl J Med1994; 330: 1679–81.
7.
FukumotoS., YamashitaT.FGF23 is a hormone-regulating phosphate metabolism-unique biological characteristics of FGF23. Bone2007; 40: 1190–5.
8.
ItohN.Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res2010; 342: 1–11.
9.
KestenbaumB., GlazerN.L., KöttgenA.. Common genetic variants associate with serum phosphorus concentration. J Am Soc Nephrol2010; 21: 1223–32.
10.
MiramsM., RobinsonB.G., MasonR.S., NelsonA.E.Bone as a source of FGF23: regulation by phosphate?Bone2004; 35: 1192–9.
11.
ShimadaT., MizutaniS., MutoT.. Cloning and characterization of FGF23 as a causative factor of tumor induced osteomalacia. Proc Natl Acad Sci USA2001; 98: 6500–5.
12.
WeberT.J., LiuS., IndridasonO.S., QuarlesL.D.Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res2003; 18: 1227–34.
13.
WernerS., DuanD.S., de VriesC., PetersK.G., JohnsonD.E., WilliamsL.T.Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities. Mol Cell Biol1992; 12: 82–8.
14.
ItohN., OrnitzD.M.Evolution of the Fgf and Fgfr gene families. Trends Genet2004; 20: 563–9.
15.
GattineniJ., BatesC., TwombleyK.. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol2009; 297: F282–91.
16.
GattineniJ., TwombleyK., GoetzR., MohammadiM., BaumM.Regulation of Serum 1,25(OH)2Vitamin D3 levels by Fibroblast Growth Factor 23 is Mediated by FGF Receptors 3 and 4. Am J Physiol Renal Physiol2011, in press
17.
UrakawaI., YamazakiY., ShimadaT.. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature2006; 444: 770–4.
18.
KurosuH., OgawaY., MiyoshiM.. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem2006; 281: 6120–3.
19.
RazzaqueM.S., LanskeB.The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol2007; 194: 1–10.
20.
YamazakiY., TamadaT., KasaiN.. Anti-FGF23 neutralizing antibodies demonstrate the physiological role and structural features of FGF23. J Bone Miner Res2008; 23: 1509–18.
21.
YuX., IbrahimiO.A., GoetzR.. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology2005; 146: 4647–56.
22.
JiippnerH.Phosphate and FGF-23. Kidney Int Suppl2011; (121): S24–7.
23.
Lavi-MoshayoffV., WassermanG., MeirT., SilverJ., Naveh-ManyT.PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol2010; 299: F882–9.
24.
SilverJ., Naveh-ManyT.FGF23 and the parathyroid glands. Pediatr Nephrol2010; 25(11): 2241–5.
25.
ShalhoubV., WardS.C., SunB.. Fibroblast Growth Factor 23 (FGF23) and Alpha-Klotho Stimulate Osteoblastic MC3T3.E1 Cell Proliferation and Inhibit Mineralization. Calcif Tissue Int2011; in press.
26.
FrishbergY., ItoN., RinatC.. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res2007; 22: 235–42.
KolekO.I., HinesE.R., JonesM.D.. 1alpha, 25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol2005; 289: G1036–42.
29.
FerrariS.L., BonjourJ.P., RizzoliR.Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab2005; 90: 519–24.
VervloetM.G., van IttersumF.J., BiittlerR.M., HeijboerA.C., BlankensteinM.A., ter Wee PM. Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol2011; 6: 383–9.
32.
ADHR Consortium.Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet2000; 26: 345–8.
33.
WaltonR.J., BijvoetO.L.Nomogram for derivation of renal threshold phosphate concentration. Lancet1975; 2: 309–10.
34.
EndoI., FukumotoS., OzonoK.. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone2008; 42: 1235–9.
35.
RendinaD., MossettiG., De FilippoG., GoffiM., StrazzulloP.Fibroblast growth factor 23 is increased in calcium nephrolithiasis with hypophosphatemia and renal phosphate leak. J Clin Endocrinol Metab2006; 91: 959–63.
36.
RendinaD., De FilippoG., TauchmanovàL.. Bone turnover and the osteoprotegerin-RANKL pathway in tumor-induced osteomalacia: a longitudinal study of five cases. Calcif Tissue Int2009; 85: 293–300.
37.
PriéD., HuartV., BakouhN.. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med2002; 347: 983–91.
38.
PriéD., RaveryV., Boccon-GibodL., FriedlanderG.Frequency of renal phosphate leak among patients with calcium nephrolithiasis. Kidney Int2001; 60: 272–6.
39.
Isakova EvenepoelP., MeijersB., ViaeneL.. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol2010; 5: 1268–76.
40.
IsakovaT., WahlP., VargasG.S.. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int2011; in press.
41.
YamashitaH., YamazakiY., HasegawaH.. Fibroblast growth factor-23 (FGF23) in patients with transient hypoparathyroidism: its important role in serum phosphate regulation. Endocr J2007; 54: 465–70.
42.
KobayashiK., ImanishiY., MiyauchiA.. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol2006; 154: 93–9.
43.
GuptaA., WinerK., EconsM.J., MarxS.J., CollinsM.T.FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab2004; 89: 4489–92.
44.
AonoY., YamazakiY., YasutakeJ.. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res2009; 24: 1879–88.
45.
AonoY., HasegawaH., YamazakiY.. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. J Bone Miner Res2011; 26: 803–10.
BastepeM., JüppnerH.Inherited hypophosphatemic disorders in children and the evolving mechanisms of phosphate regulation. Rev Endocr Metab Disord2008; 9: 171–80.
48.
RendinaD., De FilippoG., StrazzulloP.NHERF1 mutations and responsiveness of renal parathyroid hormone. N Engl J Med2008; 359: 2616–7.
